Biotechnology News

SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT...

REYKJAVIK, Iceland, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to...

Kraig Labs (OTCQB: KBLB) CEO published a thought leadership scientific opinion editorial in Biocompare, serving the life sciences and biotech research comm

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q...

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with...

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical...

NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT...

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population,...

AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive...